Gene hunt in blood cancers: could Notch1 hold clues?
NCT ID NCT07157579
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study will check for a mutation in the Notch1 gene in blood or bone marrow samples from 80 people with chronic lymphocytic leukemia (CLL) or non-Hodgkin's lymphoma (NHL). The goal is to see how common this mutation is and compare it between the two cancers. This is an observational study, meaning it does not test any new treatment, but it may help researchers learn more about these diseases.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors understand how Notch1 mutations affect CLL and NHL, possibly pointing toward better ways to predict or treat these cancers in the future.
- What could go wrong
- This is an early observational study, not a treatment trial. It only looks for a gene mutation and does not test any new drug or therapy, so it cannot directly improve patient outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2025
An estimate. Start dates often move.
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The studied individuals will be classified into 2 groups: Group (I): represent available number of CLL cases Group (II): represents available number of NHL cases
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
IncluInclusion criteria: approval to sign an informed written consent, patient with NHL and CLL . Exclusion Criteria: Refusal to sign an informed written consent, patient on chemotherapy sion Criteria:
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic lymphocytic leukemia (CLL)- non-hodgins's lymphoma (NHL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Double-Drug attack on Hard-to-Treat lymphomas
- Patient's own t cells engineered to hunt lymphoma in early trial
- Immunotherapy injection tested against Hard-to-Treat childhood lymphoma
- Vaccine aims to train immune system against blood cancers
- Can a tiny device speed up cancer diagnosis for people with HIV?
- Can a new pill shrink Hard-to-Treat tumors?